Noul has recently secured funding from the Korean government to propel its AI-driven blood analysis platform, miLab BCM, towards achieving regulatory approvals in the U.S. and Europe.
The funding, amounting to 2.2 billion won (approximately $1.6 million), is part of a multi-ministerial initiative to support advanced medical device R&D. This investment aims to facilitate multinational pivotal studies that will generate essential clinical performance data for regulatory clearance and commercialization of the miLab BCM system. Noul’s strategy includes conducting trials in various regions, including Korea, the U.S., Europe, and Latin America, to ensure the system's efficacy across diverse ethnic populations and healthcare settings.
CEO David Lim emphasized that this government backing not only affirms the potential of Noul's AI technology but also enhances their strategy for obtaining FDA 510(k) clearance and CE-IVDR certification. The company plans to initiate pivotal trials at prominent hospitals, comparing its system's performance against conventional analyzers, particularly in pediatric settings where traditional methods may fall short.
In addition to local trials, Noul is preparing for international studies to further validate diagnostic consistency across different demographics, which will be crucial for its market expansion into ten overseas territories. The miLab BCM utilizes innovative AI-based image cytometry to streamline the blood analysis process, making it particularly suitable for low-volume blood sampling, thereby addressing a significant gap in pediatric diagnostics.